...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan
【24h】

Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan

机译：日本流行性腮腺炎疫苗接种计划的疫苗接种计划的经济评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The most common preventative measure against mumps is vaccination with mumps vaccine. In most parts of the world, mumps vaccine is routinely delivered through live attenuated Measles-Mumps-Rubella (MMR) vaccine. In Japan, receiving mumps vaccine is voluntary and vaccine uptake rate is less than 30%. The introduction of mumps vaccine into routine vaccination schedule has become one of the current topics in health policy and has raised the need to evaluate efficient ways in protecting children from mumps-related diseases in Japan. We conducted a cost-effectiveness analysis with Markov model and calculated incremental cost effectiveness ratios (ICERs) of 11 different programmes; a single-dose programme at 12-16 months and 10 two-dose programmes with second dose uptakes at ages 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11. Our base-case analyse set the cost per shot at (sic)6951 (US$72; 1US$ = 96.8). Results show that single-dose programme dominates status quo. On the other hand, ICERs of all 10 two-dose programmes are under (sic)6,300,000 (US$65,082) per QALY from payer's perspective while it ranged from cost-saving to <(sic)7,000,000 (US$72,314) per QALY from societal perspective. By adopting WHO's classification that an intervention is cost-effective if ICER (in QALY) is between one and three times of GDP as a criterion, either of the vaccination programme is concluded as cost-effective from payer's or societal perspectives. Likewise, to uptake second dose at 3-5 years old is more favourable than an uptake at any other age because of lower incremental cost-effectiveness ratios
机译：预防腮腺炎最常见的措施是腮腺炎疫苗接种。在世界上大多数地区，流行性腮腺炎疫苗通常通过减毒活麻疹-流行性腮腺炎-风疹（MMR）疫苗提供。在日本，流行性腮腺炎疫苗是自愿接受的，疫苗摄取率低于30％。将流行性腮腺炎疫苗纳入常规疫苗接种计划已成为卫生政策中的当前主题之一，并提出了评估在日本保护儿童免受流行性腮腺炎相关疾病影响的有效方法的需求。我们使用马尔可夫模型进行了成本效益分析，并计算了11个不同计划的增量成本效益比（ICER）;一个12个月至16个月的单剂量方案和10个双剂量方案，并在2、3、4、5、6、7、8、9、10和11岁时接受第二剂。 （sic）6951（US $ 72; 1US $ = 96.8）。结果表明，单剂量方案主导着现状。另一方面，从付款人的角度来看，所有10个两剂计划的ICER每QALY低于（sic）6,300,000（US $ 65,082），而从社会角度来看，其成本节省范围从每QALY到<（sic）7,000,000（US $ 72,314）。 。通过采用WHO的分类标准，即如果ICER（按QALY计算）为GDP的1到3倍之间，则干预是具有成本效益的，因此，从付款人或社会的角度来看，两种疫苗接种方案均被认为具有成本效益。同样，在3-5岁时服用第二剂比在任何其他年龄服用时更有利，因为增加的成本效益比较低

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号